Company intelligence / Profile preview

Univax Biologics, Inc.

Maryland, United Statessec.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Univax Biologics developed vaccines and immunotherapies focused on stimulating plasma donor production of immunoglobulins. Its lead clinical program was a Phase 1 trial evaluating bovine anti-Cryptosporidium immunoglobulin for treating cryptosporidiosis in AIDS patients. The company merged with North American Biologicals, Inc. in the mid-1990s and is no longer active as an independent entity

Therapeutic areas: Infectious Diseases
Modalities: Immunoglobulins/vaccines
Industry: Biotech

Drug pipeline

1 asset

Cryptosporidium immune whey protein concentrate

Discontinued

Beyond the preview

Go deeper on Univax Biologics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Univax Biologics, Inc..

Explore the full profile